Soledad Bárez-López1,2, Meredith D Hartley3, Carmen Grijota-Martínez1, Thomas S Scanlan3, Ana Guadaño-Ferraz1,2. 1. 1 Instituto de Investigaciones Biomédicas Alberto Sols, Consejo Superior de Investigaciones Científicas (CSIC)-Universidad Autónoma de Madrid (UAM) , Madrid, Spain . 2. 2 Center for Biomedical Research on Rare Diseases (Ciberer), Unit 708, Instituto de Salud Carlos III , Madrid, Spain . 3. 3 Department of Physiology and Pharmacology and Program in Chemical Biology, Oregon Health and Science University , Portland, Oregon.
Abstract
BACKGROUND: Loss of function mutations in the thyroid hormone (TH)-specific cell membrane transporter, the monocarboxylate transporter 8 (MCT8), lead to profound psychomotor retardation and abnormal TH serum levels, with low thyroxine (T4) and high triiodothyronine (T3). Several studies point to impaired TH transport across brain barriers as a crucial pathophysiological mechanism resulting in cerebral hypothyroidism. Treatment options for MCT8-deficient patients are limited and are focused on overcoming the brain barriers. The aim of this study was to evaluate the ability of the TH analog sobetirome and its prodrug Sob-AM2 to access the brain and exert thyromimetic actions in the absence of Mct8. METHODS: Juvenile wild-type (Wt) mice and mice lacking Mct8 and deiodinase type 2 (Mct8/Dio2KO) were treated systemically with daily injections of vehicle, 1 mg of sobetirome/kg body weight/day, or 0.3 mg of Sob-AM2/kg body weight/day for seven days. Sobetirome content was measured using liquid chromatography-tandem mass spectrometry, and T4 and T3 levels by specific radioimmunoassays. The effect of sobetirome treatment in the expression of T3-dependent genes was measured in the heart, liver, and cerebral cortex by real-time polymerase chain reaction. RESULTS: Sob-AM2 treatment in Mct8/Dio2KO animals led to 1.8-fold more sobetirome content in the brain and 2.5-fold less in plasma in comparison to the treatment with the parent drug sobetirome. Both sobetirome and Sob-AM2 treatments in Mct8/Dio2KO mice greatly decreased plasma T4 and T3 levels. Dio1 and Ucp2 gene expression was altered in the liver of Mct8/Dio2KO mice and was not affected by the treatments. In the heart, Hcn2 but not Atp2a2 expression was increased after treatment with the analogs. Interestingly, both sobetirome and Sob-AM2 treatments increased the expression of several T3-dependent genes in the brain such as Hr, Abcd2, Mme, and Flywch2 in Mct8/Dio2KO mice. CONCLUSIONS: Sobetirome and its amide prodrug Sob-AM2 can access the brain in the absence of Mct8 and exert thyromimetic actions modulating the expression of T3-dependent genes. At the peripheral level, the administration of these TH analogs results in the depletion of circulating T4 and T3. Therefore, sobetirome and Sob-AM2 have the potential to address the cerebral hypothyroidism and the peripheral hyperthyroidism characteristic of MCT8 deficiency.
BACKGROUND: Loss of function mutations in the thyroid hormone (TH)-specific cell membrane transporter, the monocarboxylate transporter 8 (MCT8), lead to profound psychomotor retardation and abnormal TH serum levels, with low thyroxine (T4) and high triiodothyronine (T3). Several studies point to impaired TH transport across brain barriers as a crucial pathophysiological mechanism resulting in cerebral hypothyroidism. Treatment options for MCT8-deficientpatients are limited and are focused on overcoming the brain barriers. The aim of this study was to evaluate the ability of the TH analog sobetirome and its prodrug Sob-AM2 to access the brain and exert thyromimetic actions in the absence of Mct8. METHODS: Juvenile wild-type (Wt) mice and mice lacking Mct8 and deiodinase type 2 (Mct8/Dio2KO) were treated systemically with daily injections of vehicle, 1 mg of sobetirome/kg body weight/day, or 0.3 mg of Sob-AM2/kg body weight/day for seven days. Sobetirome content was measured using liquid chromatography-tandem mass spectrometry, and T4 and T3 levels by specific radioimmunoassays. The effect of sobetirome treatment in the expression of T3-dependent genes was measured in the heart, liver, and cerebral cortex by real-time polymerase chain reaction. RESULTS:Sob-AM2 treatment in Mct8/Dio2KO animals led to 1.8-fold more sobetirome content in the brain and 2.5-fold less in plasma in comparison to the treatment with the parent drug sobetirome. Both sobetirome and Sob-AM2 treatments in Mct8/Dio2KO mice greatly decreased plasma T4 and T3 levels. Dio1 and Ucp2 gene expression was altered in the liver of Mct8/Dio2KO mice and was not affected by the treatments. In the heart, Hcn2 but not Atp2a2 expression was increased after treatment with the analogs. Interestingly, both sobetirome and Sob-AM2 treatments increased the expression of several T3-dependent genes in the brain such as Hr, Abcd2, Mme, and Flywch2 in Mct8/Dio2KO mice. CONCLUSIONS:Sobetirome and its amide prodrug Sob-AM2 can access the brain in the absence of Mct8 and exert thyromimetic actions modulating the expression of T3-dependent genes. At the peripheral level, the administration of these TH analogs results in the depletion of circulating T4 and T3. Therefore, sobetirome and Sob-AM2 have the potential to address the cerebral hypothyroidism and the peripheral hyperthyroidism characteristic of MCT8 deficiency.
Authors: Joke Delbaere; Pieter Vancamp; Stijn L J Van Herck; Nele M A Bourgeois; Mary J Green; Richard J T Wingate; Veerle M Darras Journal: J Endocrinol Date: 2016-11-22 Impact factor: 4.286
Authors: S U Trost; E Swanson; B Gloss; D B Wang-Iverson; H Zhang; T Volodarsky; G J Grover; J D Baxter; G Chiellini; T S Scanlan; W H Dillmann Journal: Endocrinology Date: 2000-09 Impact factor: 4.736
Authors: Eva K Wirth; Stephan Roth; Cristiane Blechschmidt; Sabine M Hölter; Lore Becker; Ildiko Racz; Andreas Zimmer; Thomas Klopstock; Valerie Gailus-Durner; Helmut Fuchs; Wolfgang Wurst; Thomas Naumann; Anja Bräuer; Martin Hrabé de Angelis; Josef Köhrle; Annette Grüters; Ulrich Schweizer Journal: J Neurosci Date: 2009-07-29 Impact factor: 6.167
Authors: Meredith D Hartley; Tania Banerji; Ian J Tagge; Lisa L Kirkemo; Priya Chaudhary; Evan Calkins; Danielle Galipeau; Mitra D Shokat; Margaret J DeBell; Shelby Van Leuven; Hannah Miller; Gail Marracci; Edvinas Pocius; Tapasree Banerji; Skylar J Ferrara; J Matthew Meinig; Ben Emery; Dennis Bourdette; Thomas S Scanlan Journal: JCI Insight Date: 2019-04-18
Authors: Xiao-Hui Liao; Pablo Avalos; Oksana Shelest; Raz Ofan; Michael Shilo; Catherine Bresee; Shibi Likhite; Jean-Philippe Vit; Heike Heuer; Brian Kaspar; Kathrin Meyer; Alexandra M Dumitrescu; Samuel Refetoff; Clive N Svendsen; Gad D Vatine Journal: Thyroid Date: 2022-05-20 Impact factor: 6.506
Authors: P Chaudhary; G H Marracci; E Calkins; E Pocius; A L Bensen; T S Scanlan; B Emery; D N Bourdette Journal: J Neuroimmunol Date: 2020-12-27 Impact factor: 3.478
Authors: Ferdy S van Geest; Nilhan Gunhanlar; Stefan Groeneweg; W Edward Visser Journal: Front Endocrinol (Lausanne) Date: 2021-09-01 Impact factor: 5.555
Authors: Carmen Grijota-Martínez; Soledad Bárez-López; David Gómez-Andrés; Ana Guadaño-Ferraz Journal: Front Neurosci Date: 2020-04-28 Impact factor: 4.677